Oral GnRH Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant ADT to EBRT in Localized Intermediate-Risk Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-Risk Prostate Cancer: A Randomised, Open-Label, Parallel-Group Phase 2 Trial
Eur Urol 2020 Apr 06;[EPub Ahead of Print], DP Dearnaley, DR Saltzstein, JE Sylvester, L Karsh, BA Mehlhaff, C Pieczonka, JL Bailen, H Shi, Z Ye, HM Faessel, H Lin, Y Zhu, F Saad, DB MacLean, ND ShoreFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.